Right-to-Try is legislation that allows terminally ill patients to access investigational treatments which have passed Phase I testing through the Food and Drug Administration (FDA), but are not available yet to the public because they have not yet been approved by the FDA. Join us for this informative webinar where Professor Bateman-House, Assistant Professor in the Division of Medical Ethics at New York University Langone Medical Center, will discuss the legislation, break down the language, and explain how Right-to-Try can affect cancer patients.
Your registration is important -even if you can’t attend live we’ll share the slides, video & audio of the presentation directly to you!
About the Presenter
Alison Bateman-House, PHD, MPH, MA
Alison Bateman-House, PHD, MPH, MA, is an Assistant Professor in the Division of Medical Ethics at New York University Langone Medical Center. She has advanced training in bioethics, public health, and history, and she specializes in the ethics and history of human subjects research and the ethics and history of public health.
Alison Bateman-House serves as the non-voting, nonpaid deputy chairperson of the Compassionate Use Advisory Committee (CompAC), an external, expert panel of internationally recognized medical experts, bioethicists, and patient representatives formed by NYU School of Medicine, which advises the Janssen division of Johnson and Johnson about requests for compassionate use of some of its investigational medicines.
She also co-chairs the NYU School of Medicine Working Group on Compassionate Use and Pre-Approval Access.